Risks of gene therapy should be weighed against lack of alternatives for many diseasesBMJ 2005; 330 doi: http://dx.doi.org/10.1136/bmj.330.7494.791-a (Published 31 March 2005) Cite this as: BMJ 2005;330:791
- Robert E MacLaren, MRC research fellow,
- Robin R Ali, professor of human molecular genetics,
- Adrian J Thrasher, professor of paediatric immunology
- Division of Molecular Therapy, Institute of Ophthalmology, University College London, London EC1V 9EL
- Molecular Immunology Unit, Institute of Child Health, UCL, London WC1N 1EH
EDITOR—Kimmelman provided a comprehensive discussion about the risks and ethics of gene therapy.1 We certainly cannot predict the future, but the risks should be weighed against the complete lack of alternative options for many of the diseases discussed.
The two cases of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial